Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor: The SWAP (SWitching Anti Platelet)-3 Study
Phase of Trial: Phase IV
Latest Information Update: 20 Oct 2016
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary) ; Prasugrel
- Indications Acute coronary syndromes; Thrombosis
- Focus Pharmacodynamics
- Acronyms SWAP-3
- 31 Aug 2018 Biomarkers information updated
- 12 Nov 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 04 Mar 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.